ArticleChemical science2019
Monodisperse polysarcosine-based highly-loaded antibody-drug conjugates.
Article in Chemical science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 90 citations in OpenAlex.
- Development of a Polypeptide-Based Platform to Construct Antibody-Drug Conjugates with High Potency.JACS Au · 2026Article
- Therapeutic peptides and proteins: Status and developments in drug delivery.Journal of controlled release : official journal of the Controlled Release Society · 2026Review
- Challenges and Opportunities for Cleavable Linkers Used in Polymer-Drug Conjugates.Journal of the American Chemical Society · 2026Review
- Site-Specific Glycan Conjugation Improves Stability and Efficacy of an Antibody-Drug Conjugates Bearing DXd as a Cytotoxic Payload.ACS omega · 2026Article
- Toward Prostate Cancer Early Warning with a Self-Powered Wearable Biosensing Platform Integrated with Machine Learning.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- GD2-Targeted Minibody-Drug Conjugates Match the Potency of IgG-Based ADCs in a Mouse Cancer Model.International journal of molecular sciences · 2026Article
- Antibody-Drug Conjugates in Breast Cancer: Therapeutic-Window Engineering, Tumor Heterogeneity, and Immunotherapy Combinations.Drug design, development and therapy · 2026Review
- Preclinical Characterization of XB010: A Novel Antibody-Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4.Molecular cancer therapeutics · 2025Article
- Safe and Efficient Intracellular Release of SN38 via Lysosomal-Responsive SN38-G Loaded Liposomes.ACS applied bio materials · 2025Article
- Methods for the Generation of Single-Payload Antibody-Drug Conjugates.ChemMedChem · 2025Article
- Branched Linkers for Homogeneous Antibody-Drug Conjugates: How Long Is Long Enough?International journal of molecular sciences · 2024Article
- ETx-22, a Novel Nectin-4-Directed Antibody-Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4-Expressing Tumors.Cancer research communications · 2024Article
- Exo-Cleavable Linkers: Enhanced Stability and Therapeutic Efficacy in Antibody-Drug Conjugates.Journal of medicinal chemistry · 2024Article
- Antibody-drug conjugates in solid tumors; new strategy for cancer therapy.Japanese journal of clinical oncology · 2024Review
- Homogeneous multi-payload antibody-drug conjugates.Nature chemistry · 2024Review
- Exploring the next generation of antibody-drug conjugates.Nature reviews. Clinical oncology · 2024Review
- Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice.Experimental hematology & oncology · 2024Review
- Transmembrane signaling by a synthetic receptor in artificial cells.Nature communications · 2023Article
- Compact hydrophilic electrophiles enable highly efficacious high DAR ADCs with excellentChemical science · 2023Article
- A Review of Protein- and Peptide-Based Chemical Conjugates: Past, Present, and Future.Pharmaceutics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibody-drug conjugates (ADCs) convey highly potent anticancer drugs to antigen-expressing tumor cells, thereby sparing healthy tissues throughout the body. Pharmacokinetics and tolerability of ADCs are predominantly influenced by the drug-antibody ratio (DAR) of the conjugates, which is to-date limited to a value of 3-4 drugs per antibody in ADCs under clinical investigations. Here, we report the synthesis of monodisperse (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.